$MIRM News

RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $148

Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio

JP Morgan Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $125

The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib

Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?

Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?

Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $146

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $150

Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress

Citigroup Initiates Coverage On Mirum Pharmaceuticals with Buy Rating, Announces Price Target of $145

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance

Mirum’s US$600 Million Zero-Coupon Convertible Note Issue Might Change The Case For Investing In Mirum Pharmaceuticals (MIRM)

Mirum Pharma: A Rare Disease Growth Story to Watch

Wolfe Research Initiates Coverage On Mirum Pharmaceuticals with Outperform Rating, Announces Price Target of $145

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

Mirum Pharmaceuticals Announces Proposed $600M Offering Of Notes Due 2032